4Moving Biotech announces successful results from its Lasare Phase I 4P004 Clinical Trial intraarticular Liraglutide for knee osteoarthritis patients
10.6.2024 08:30:00 EEST | Business Wire | Press release
4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis (OA) patients using 4P004.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609275171/en/
(Graphic: Business Wire)
Lasare Phase I trial is a multi-center, randomized, double-blinded, placebo-controlled involving 34 patients across three sites in Belgium.
The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004).
The trial reached its primary objective, confirming that intraarticular liraglutide (4P004) was safe and well tolerated. A pharmacological active dose has been identified, with similar expected adverse events (EAEs) in the 4P004 groups as the placebo group. Pharmacokinetics, both observed and simulated Cmax values, also indicated lower systemic exposure than reported for subcutaneous liraglutide injection from the approved product, Victoza®, affirming the company’s plan to pursue a 505(b)(2) regulatory pathway in the US for 4P004.
Pr. Francis Berenbaum, Co-founder and Chief Medical Officer of 4Moving Biotech, declared: "The Success of the Phase 1 study of 4P004 underscores the quality of our advancements in the quest for therapeutic solutions for patients suffering from knee osteoarthritis. Furthermore, with the established safety and tolerability profiles, we are progressing confidently to the next stage of clinical development with 4P004."
As for ultimate goal, 4Moving Biotech’s strategy intends to secure accelerated approvals in the US and EU for early market entry at the end of the planned Phase 2b efficacy and safety trial. Toward this goal, the company recently received constructive pre-IND guidance from the FDA, translating 4Moving Biotech’s planned potential accelerated approval driven strategy into a highly differentiated clinical program catalyzed by a unique combination of reasonably likely surrogate endpoints, supported by sophisticated in silico AI-based prognostic modelling.
Revital Rattenbach, Chairwoman of 4Moving Biotech, stated: "Beyond the positive results from our phase I clinical study on knee osteoarthritis, the FDA's positive echoing has built a tremendous momentum for our accelerated strategy to the market, with hopes to bring to OA patients the first therapy being able to modify the natural course of the disease."
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
About Lasare
This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program. The funding agencies supporting this work are (in alphabetical order of participating countries): France: BPI France ; Germany: Project Management Agency (DLR), which acts on behalf of the Federal Ministry of Education and Research (BMBF); The Netherlands: Netherlands Enterprise Agency (RVO); Switzerland: Innosuisse (the Swiss Innovation Agency).
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609275171/en/
Contact information
Press :
Emmanuel Dadje
Communication Manager
+33 6 30 06 12 13
emmanuel.dadje@4P-Pharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Canva Introduces Magic Layers, Turning Static AI Outputs Into Editable Designs11.3.2026 15:00:00 EET | Press release
Canva, the world's leading all-in-one visual communication platform, today unveiled Magic Layers, a new breakthrough technology that turns any flat design or image into something you can edit, refine, and remix to suit your vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311951174/en/ Magic Layers is a new breakthrough technology that turns any flat design or image into something you can edit, refine, and remix to suit your vision. Generative AI has triggered a flood of visual content, but most of it remains locked in static image files. Even small changes can require starting over, with reprompts that can unintentionally alter the entire design. Powered by years of internal research and Canva’s growing investment in its AI development arm, Magic Layers ushers in a new era of editable content, where speed meets true creative control. Available in public beta today, it turns AI-generated content into a launchpad, no
Adtran plays key role in OIF’s OFC 2026 interoperability demo with FSP 3000 OLS, ZR+ coherent plugs and domain controller11.3.2026 15:00:00 EET | Press release
Adtran today announced it’s playing a key role in the OIF’s multi-vendor interoperability demo at OFC 2026. The showcase brings together 40 member companies, highlighting real‑world operation across open optical networks. It validates multi‑vendor 100Gbit/s, 400Gbit/s and 800Gbit/s ZR+ coherent pluggable transceivers operating over open line systems. Featuring Adtran’s FSP 3000 OLS, coherent ZR+ pluggable optics and Mosaic Network Controller, the setup extends previous years’ configurations to include C‑ and L‑band operation and multi‑layer domain control. Adtran’s 800Gbit/s ZR+ pluggables also feature in the OIF plugfest, reinforcing their role in large‑scale, multi-vendor environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311198561/en/ Adtran’s open networking technology will be central to the OIF multi-vendor interoperability demo at OFC 2026. “Interoperability is the foundation that enables open optical netw
Xsolla Releases New Industry Report Identifying the Biggest Opportunities for the Future of Video Games for Developers11.3.2026 15:00:00 EET | Press release
Xsolla, a leading global video game commerce company, today released the latest edition of The Xsolla Report, timed to coincide with this week's activations and collaborations in San Francisco. This edition provides insights from working with thousands of studios to map out where the industry’s biggest opportunities are emerging. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311021020/en/ Graphic: Xsolla The gaming industry remains extraordinarily vibrant, and the playbook for success is changing. Studios that are adapting their commercial strategies, embracing direct-to-player commerce, expanding into high-growth global markets, and leveraging AI to sharpen operations are pulling ahead and building businesses designed to thrive for years to come. "The economics of game development have and will continue to shift and evolve into the future. Budgets have expanded, player acquisition costs have surged, and traditional publ
SES Launches Cash Tender Offer11.3.2026 14:25:00 EET | Press release
THIS ANNOUNCEMENT RELATES TO THE DISCLOSURE OF INFORMATION THAT QUALIFIED OR MAY HAVE QUALIFIED AS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE MARKET ABUSE REGULATION (EU) 596/2014. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES (the “Offeror”) announces today that it is inviting holders of its outstanding €625,000,000 Deeply Subordinated Fixed Rate Re
Thredd and Cross River to Accelerate Expansion into the US Market for Global Fintechs11.3.2026 14:01:00 EET | Press release
Thredd, the AI-first issuer processing platform, today announced a strategic alliance with Cross River Bank (“Cross River”), a technology infrastructure provider that offers embedded financial solutions. The relationship is designed to accelerate the entry of international fintechs into the United States. This collaboration leverages Thredd’s global expertise and technology stack with Cross River’s proprietary core infrastructure, established market leadership and regulatory expertise, creating a seamless pathway for innovative payment solutions to launch and scale in the U.S. As part of this agreement, Thredd becomes one of Cross River’s select strategic processing partners outside of the bank’s own stack. The arrangement enables Thredd to introduce a curated pipeline of high-potential fintech clients from various geographic regions*.1 In turn, Thredd’s clients benefit from Cross River’s proven ability to deliver compliant, scalable banking infrastructure and principal network sponsor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom